HomeMarket NewsMicro Cap StocksInvestors Cheer as Apollomics Secures Conditional Approval for Cancer Drug in China

Investors Cheer as Apollomics Secures Conditional Approval for Cancer Drug in China

Actionable Trade Ideas

always free


Apollomics Inc’sΒ APLM partner in China,Β Avistone Biotechnology Co. Ltd., has received conditional approval from the National Medical Products Administration (NMPA) of China for the commercialization of vebreltinib toΒ treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC).

In active pursuit of the MET exon 14 skipping NSCLC indication, Apollomics is engaged in discussions with the FDA regarding a New Drug Application (NDA) for vebreltinib, drawing on the totality of clinical data from the global SPARTA trial and Avistone’s KUNPENG trial in China.

NSCLC accounts for about 85% of all lung cancer cases and remains a top cause of cancer-related deaths globally.Β 

Patients with MET exon 14 skipping mutations comprise about 3% to 4% of all NSCLC cases.

Under the partnership agreement, Avistone holds the exclusive rights to vebreltinib in China, Hong Kong, and Macau, while Apollomics retains the exclusive rights in the rest of the world, including the U.S., and partners have access to each other’s data.Β 

Price Action:Β APLM shares have surged by 44.8% to $1.26 on the last check Thursday.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.